Is brigatinib the preferred drug for lung cancer?

The priority drug for lung cancer is not necessarily brigatinib, but needs to be comprehensively determined based on the patient's specific situation, including the type, stage, gene mutation status of the lung cancer, and the patient's physical condition. As an ALK tyrosine kinase inhibitor, brigatinib is indeed an important drug in the treatment of lung cancer under certain circumstances, but it is not suitable for all patients with lung cancer.

Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer includes adenocarcinoma, squamous cell carcinoma and other subtypes. Brigatinib is mainly used to treat patients with ALK positive non-small cell lung cancer. For these patients, brigatinib can significantly inhibit tumor growth and prolong survival. However, brigatinib may not be suitable for ALK-negative patients or other types of lung cancer.

Even for patients with ALK-positive non-small cell lung cancer, brigatinib is not necessarily the drug of choice. Currently, there are many choices for drugs targeting the ALK gene, including crizotinib, alectinib, etc. These drugs have their own characteristics in terms of efficacy, safety and drug resistance. Doctors will choose appropriate drugs for treatment based on the patient's specific conditions.

The treatment of lung cancer does not rely solely on targeted drugs, but requires the comprehensive use of multiple treatments such as surgery, radiotherapy, and chemotherapy. For patients with early-stage lung cancer, surgery is the preferred treatment method; for advanced-stage patients, chemotherapy, radiotherapy and other means may be needed to control the disease. Therefore, when determining a treatment plan, doctors will comprehensively consider the patient's condition and needs and develop a personalized treatment plan.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10789949/